Adrenal insufficiency in corticosteroids use: Systematic review and meta-analysis

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 6, 2015, Pages 2171-2180

  Broersen, Leonie H A ^a   Pereira, Alberto M ^a   Jørgensen, Jens Otto L ^b   Dekkers, Olaf M ^a,b,c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DRUG DOSAGE FORM;

ADRENAL INSUFFICIENCY; ARTICLE; ASTHMA; ATOPIC DERMATITIS; BRONCHIECTASIS; CARCINOMA; CROHN DISEASE; CYSTIC FIBROSIS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG USE; DRUG WITHDRAWAL; GIANT CELL ARTERITIS; GLAUCOMA; HEMATOLOGIC MALIGNANCY; HUMAN; LICHEN PLANUS; LONG TERM CARE; LOW DRUG DOSE; META ANALYSIS; NOSE POLYP; OSTEOARTHRITIS; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; RHINITIS; RHINOSINUSITIS; RISK FACTOR; SHORT COURSE THERAPY; SYSTEMATIC REVIEW; TREATMENT DURATION; ADULT; ADVERSE EFFECTS; CHEMICALLY INDUCED; DRUG ADMINISTRATION; DRUG ADMINISTRATION ROUTE; DRUG DOSAGE FORM; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; NEOPLASMS; ORGAN TRANSPLANTATION; PROCEDURES; SKIN DISEASES; STATISTICS AND NUMERICAL DATA;

ADRENAL CORTEX HORMONES; ADRENAL INSUFFICIENCY; ADULT; DOSAGE FORMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFLAMMATION; NEOPLASMS; ORGAN TRANSPLANTATION; SKIN DISEASES; TRANSPLANTATION CONDITIONING;

EID: 84930787882     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-1218     Document Type: Article

References (95)

1. Rodger RS, Watson MJ, Sellars L, Wilkinson R, Ward MK, Kerr DN. Hypothalamic-pituitary-adrenocortical suppression and recovery in renal transplant patients returning to maintenance dialysis. Q J Med. 1986;61(235):1039-1046.
2. Spiegel RJ, Vigersky RA, Oliff AI, Echelberger CK, Bruton J, Poplack DG. Adrenal suppression after short-term corticosteroid therapy. Lancet. 1979;1(8117):630-633.
3. van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids in the United Kingdom. QJM. 2000;93(2):105-111.
4. Arlt W, Allolio B. Adrenal insufficiency. Lancet. 2003;361(9372):1881-1893.
5. Oelkers W. Adrenal insufficiency. N Engl J Med. 1996;335(16):1206-1212.
6. Chrousos GP, Harris AG. Hypothalamic-pituitary-adrenal axis suppression and inhaled corticosteroid therapy. 1. General principles. Neuroimmunomodulation. 1998;5(6):277-287.
7. Christy NP. HPA failure and glucocorticoid therapy. Hosp Pract Off Ed. 1984;19(7):77-79, 83-84, 87-89, concl.
8. Jamilloux Y, Liozon E, Pugnet G, et al. Recovery of adrenal function after long-term glucocorticoid therapy for giant cell arteritis: a cohort study. PLoS One. 2013;8(7):e68713.
9. Krasner AS. Glucocorticoid-induced adrenal insufficiency. JAMA. 1999;282(7):671-676.
10. Schlaghecke R, Kornely E, Santen RT, Ridderskamp P. The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med. 1992;326(4):226-230.
11. LaRochelle GE Jr, LaRochelle AG, Ratner RE, Borenstein DG. Recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients with rheumatic diseases receiving low-dose prednisone. Am J Med. 1993;95(3):258-264.
12. Grinspoon SK, Biller BM. Clinical review 62: Laboratory assessment of adrenal insufficiency. J Clin Endocrinol Metab. 1994;79(4):923-931.
13. Plumpton FS, Besser GM. The adrenocortical response to surgery and insulin-induced hypoglycaemia in corticosteroid-treated and normal subjects. Br J Surg. 1969;56(3):216-219.
14. Gonzálbez J, Villabona C, Ramón J, et al. Establishment of reference values for standard dose short synacthen test (250 microgram), low dose short synacthen test (1 microgram) and insulin tolerance test for assessment of the hypothalamo-pituitary-adrenal axis in normal subjects. Clin Endocrinol (Oxf). 2000;53(2):199-204.
15. Ficher M, Curtis GC, Ganjam CK, Joshlin L, Perry S. Improved measurement of corticosteroids in plasma and urine by competitive protein-binding radioassay. Clin Chem. 1973;19(5):511-515.
16. Dekkers OM, Egger M, Altman DG, Vandenbroucke JP. Distinguishing case series from cohort studies. Ann Intern Med. 2012; 156:37-40.
17. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-2012.
18. Thamboo A, Manji J, Szeitz A, et al. The safety and efficacy of short-term budesonide delivered via mucosal atomization device for chronic rhinosinusitis without nasal polyposis. Int Forum Allergy Rhinol. 2014;4:397-402.
19. Allenby CF, Main RA, Marsden RA, Sparkes CG. Effect on adrenal function of topically applied clobetasol propionate (Dermovate). Br Med J. 1975;4(5997):619-621.
20. Svendsen UG, Frølund L, Heinig JH, Madsen F, Nielsen NH, Weeke B. High-dose inhaled steroids in the management of asthma. A comparison of the effects of budesonide and beclomethasone dipropionate on pulmonary function, symptoms, bronchial responsiveness and the adrenal function. Allergy. 1992;47:174-180.
21. Brown PH, Greening AP, Crompton GK. Large volume spacer devices and the influence of high dose beclomethasone dipropionate on hypothalamo-pituitary-adrenal axis function. Thorax. 1993;48(3):233-238.
22. Carella MJ, Srivastava LS, Gossain VV, Rovner DR. Hypothalamic-pituitary-adrenal function one week after a short burst of steroid therapy. J Clin Endocrinol Metab. 1993;76(5):1188-1191.
23. Visscher HW, Ebels JT, Roders GA, Jonkman JG. Randomised crossover comparison of adrenal suppressive effects of dermal creams containing glucocorticosteroids. Eur J Clin Pharmacol. 1995;48(2):123-125.
24. Wasserman SI, Gross GN, Schoenwetter WF, et al. A 12-week dose-ranging study of fluticasone propionate powder in the treatment of asthma. J Asthma. 1996;33(4):265-274.
25. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology. 1996;110(1):45-51.
26. Clark DJ, Lipworth BJ. Evaluation of corticotropin releasing factor stimulation and basal markers of hypothalamic-pituitary-adrenal axis suppression in asthmatic patients. Chest. 1997;112(5):1248-1252.
27. Wilson AM, McFarlane LC, Lipworth BJ. Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenal-axis activity. J Allergy Clin Immunol. 1998;101:470-474.
28. Aaronson D, Kaiser H, Dockhorn R, et al. Effects of budesonide by means of the Turbuhaler on the hypothalmic-pituitary-adrenal axis in asthmatic subjects: a dose-response study. J Allergy Clin Immunol. 1998;101(3):312-319.
29. Vargas R, Dockhorn RJ, Findlay SR, Korenblat PE, Field EA, Kral KM. Effect of fluticasone propionate aqueous nasal spray versus oral prednisone on the hypothalamic-pituitary-adrenal axis. J Allergy Clin Immunol. 1998;102(2):191-197.
30. Gazis AG, Homer JJ, Henson DB, Page SR, Jones NS. The effect of six weeks topical nasal betamethasone drops on the hypothalamo-pituitary-adrenal axis and bone turnover in patients with nasal polyposis. Clin Otolaryngol Allied Sci. 1999;24(6):495-498.
31. Franz TJ, Parsell DA, Halualani RM, Hannigan JF, Kalbach JP, Harkonen WS. Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol. 1999;38(8):628-632.
32. Sorkness CA, LaForce C, Storms W, Lincourt WR, Edwards L, Rogenes PR. Effects of the inhaled corticosteroids fluticasone propionate, triamcinolone acetonide, and flunisolide and oral prednisone on the hypothalamic-pituitary-adrenal axis in adult patients with asthma. Clin Ther. 1999;21(2):353-367.
33. Nelson HS, Busse WW, deBoisblanc BP, et al. Fluticasone propionate powder: oral corticosteroid-sparing effect and improved lung function and quality of life in patients with severe chronic asthma. J Allergy Clin Immunol. 1999;103:267-275.
34. Li JT, Goldstein MF, Gross GN, et al. Effects of fluticasone propionate, triamcinolone acetonide, prednisone, and placebo on the hypothalamic-pituitary-adrenal axis. J Allergy Clin Immunol. 1999;103(4):622-629.
35. Wilson AM, Sims EJ, Lipworth BJ. Dose response with fluticasone propionate on adrenocortical activity and recovery of basal and stimulated responses after stopping treatment. Clin Endocrinol (Oxf). 1999;50(3):329-335.
36. Gupta D, Behera D, Lalrinmawia H, Dash RJ. Hypothalamo-pituitary-adrenal axis function in asthmatics taking low dose inhaled beclomethasone dipropionate. J Assoc Physicians India. 2000;48(7):682-684.
37. Affrime MB, Kosoglou T, Thonoor CM, Flannery BE, Herron JM. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. Chest. 2000;118(6):1538-1546.
38. Nelson HS, Kane RE, Petillo J, Banerji D. Long-term safety of a non-chlorofluorocarbon-containing triamcinolone acetonide inhalation aerosol in patients with asthma. Azmacort HFA Study Group. J Asthma. 2000;37(2):145-152.
39. Boots JM, van den Ham EC, Christiaans MH, van Hooff JP. Risk of adrenal insufficiency with steroid maintenance therapy in renal transplantation. Transplant Proc. 2002;34(5):1696-1697.
40. Niitsuma T, Okita M, Sakurai K, et al. Adrenal function as assessed by low-dose adrenocorticotropin hormone test before and after switching from inhaled beclomethasone dipropionate to inhaled fluticasone propionate. J Asthma. 2003;40(5):515-522.
41. Patel RS, Shaw SR, Wallace AM, McGarry GW. Efficacy and systemic tolerability of mometasone furoate and betamethasone sodium phosphate. J Laryngol Otol. 2004;118(11):866-871.
42. Lee DK, Bates CE, Currie GP, Cowan LM, McFarlane LC, Lipworth BJ. Effects of high-dose inhaled fluticasone propionate on the hypothalamic-pituitary-adrenal axis in asthmatic patients with severely impaired lung function. Ann Allergy Asthma Immunol. 2004;93(3):253-258.
43. Kirwan JR, Hickey SH, Hällgren R, et al. The effect of therapeutic glucocorticoids on the adrenal response in a randomized controlled trial in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(5):1415-1421.
44. Schlessinger J, Miller B, Gilbert RD, Plott RT. An open-label adrenal suppression study of 0.1% fluocinonide cream in pediatric patients with atopic dermatitis. Arch Dermatol. 2006;142(12):1568-1572.
45. Andres P, Poncet M, Farzaneh S, Soto P. Short-term safety assessment of clobetasol propionate 0.05% shampoo: hypothalamic-pituitary-adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis. J Drugs Dermatol. 2006;5(4):328-332.
46. White M, Crisalida T, Li H, Economides A, Kaliner M. Effects of long-term inhaled corticosteroids on adrenal function in patients with asthma. Ann Allergy Asthma Immunol. 2006;96(3):437-444.
47. Duclos M, Guinot M, Colsy M, et al. High risk of adrenal insufficiency after a single articular steroid injection in athletes. Med Sci Sports Exerc. 2007;39(7):1036-1043.
48. Fleming C, Ganslandt C, Leese GP. Short- and long-term safety assessment of a two-compound ointment containing calcipotriene/betamethasone dipropionate (Taclonex/Daivobet/Dovobet ointment): hypothalamic-pituitary-adrenal axis function in patients with psoriasis vulgaris. J Drugs Dermatol. 2010;9(8):969-974.
49. Neidert S, Schuetz P, Mueller B, Christ-Crain M. Dexamethasone suppression test predicts later development of an impaired adrenal function after a 14-day course of prednisone in healthy volunteers. Eur J Endocrinol. 2010;162(5):943-949.
50. Moghaddam KG, Rashidi N, Meybodi HA, et al. The effect of inhaled corticosteroids on hypothalamic-pituitary-adrenal axis. Indian J Pharmacol. 2012;44(3):314-318.
51. Habib G, Artul S, Chernin M, Hakim G, Jabbour A. The effect of intra-articular injection of betamethasone acetate/betamethasone sodium phosphate at the knee joint on the hypothalamic-pituitaryadrenal axis: a case-controlled study. J Investig Med. 2013;61(7): 1104-1107.
52. Silver S, Tuppal R, Gupta AK, et al. Effect of calcipotriene plus betamethasone dipropionate topical suspension on the hypothalamic-pituitary-adrenal axis and calcium homeostasis in subjects with extensive psoriasis vulgaris: an open, non-controlled, 8-week trial. J Drugs Dermatol. 2013;12(8):882-887.
53. Habib G, Khazin F, Jabbour A, et al. Simultaneous bilateral knee injection of methylprednisolone acetate and the hypothalamic-pituitary adrenal axis: a single-blind case-control study. J Investig Med. 2014;62:621-626.
54. Habib G, Jabbour A, Artul S, Hakim G. Intra-articular methylprednisolone acetate injection at the knee joint and the hypothalamicpituitary-adrenal axis: a randomized controlled study. Clin Rheumatol. 2014;33(1):99-103.
55. Bondarevsky E, Shapiro MS, Schey G, Shahor J, Bruderman I. Beclomethasone dipropionate use in chronic asthmatic patients. Effect on adrenal function after substitution for oral glucocorticosteroids. JAMA. 1976;236(17):1969-1971.
56. Krupin T, Mandell AI, Podos SM, Becker B. Topical corticosteroid therapy and pituitary-adrenal function. Arch Ophthalmol. 1976;94(6):919-920.
57. Canafax DM, Mann HJ, Sutherland DE, Simmons RL, Najarian JS. The use of a cosyntropin stimulation test to predict adrenal suppression in renal transplant patients being withdrawn from prednisone. Transplantation. 1983;36(2):143-146.
58. Bromberg JS, Alfrey EJ, Barker CF, et al. Adrenal suppression and steroid supplementation in renal transplant recipients. Transplantation. 1991;51(2):385-390.
59. Hirano T, Shimodaira H, Oka K, et al. Comparative study of adrenocortical function in renal transplant recipients under different long-term immunosuppressive therapy. Transplant Proc. 1993;25: 1359-1360.
60. Hasegawa T, Ishihara K, Fujii H, et al. Influence of high dose inhaled steroids on hypothalamo-pituitary-adrenal axis function in Japanese patients with asthma: a comparison over the course of time. Intern Med. 1996;35(5):362-366.
61. Grebe SK, Feek CM, Durham JA, Kljakovic M, Cooke RR. Inhaled beclomethasone dipropionate suppresses the hypothalamo-pituitary-adrenal axis in a dose dependent manner. Clin Endocrinol (Oxf). 1997;47(3):297-304.
62. Gellner R, Stange M, Schiemann U, Domschke W, Hengst K. CRH test prior to discontinuation of long-term low-dose glucocorticoid therapy. Exp Clin Endocrinol Diabetes. 1999;107(8):561-567.
63. Henzen C, Suter A, Lerch E, Urbinelli R, Schorno XH, Briner VA. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet. 2000;355(9203):542-545.
64. Skov M, Main KM, Sillesen IB, Müller J, Koch C, Lanng S. Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide. Eur Respir J. 2002;20(1):127-133.
65. Kos-Kudła B, Ciesielska-Kopacz N, Ostrowska Z, et al. Adrenal cortex function in asthmatic patients following the discontinuation of chronic therapy with systemic glucocorticosteroids. J Clin Pharm Ther. 2003;28(2):103-108.
66. Nguyen KL, Lauver D, Kim I, Aresery M. The effect of a steroid "burst" and long-term, inhaled fluticasone propionate on adrenal reserve. Ann Allergy Asthma Immunol. 2003;91(1):38-43.
67. Baz-Hecht M, Osher E, Yachnin T, et al. The low-dose (1 microg) adrenocorticotropin stimulation test in kidney and kidney-pancreas transplant patients: a potential guideline for steroid withdrawal. Clin Transplant. 2006;20(1):72-77.
68. Gonzalez-Moles MA, Scully C. HPA-suppressive effects of aqueous clobetasol propionate in the treatment of patients with oral lichen planus. J Eur Acad Dermatol Venereol. 2010;24(9):1055-1059.
69. Sandhu SS, Smith JM, Doherty M, James A, Figueiredo FC. Do topical ophthalmic corticosteroids suppress the hypothalmic-pituitary-adrenal axis in post-penetrating keratoplasty patients? Eye (Lond). 2012;26(5):699-702.
70. Han HS, Shim YK, Kim JE, et al. A pilot study of adrenal suppression after dexamethasone therapy as an antiemetic in cancer patients. Support Care Cancer. 2012;20(7):1565-1572.
71. Gilchrist FJ, Cox KJ, Rowe R, et al. Itraconazole and inhaled fluticasone causing hypothalamic-pituitary-adrenal axis suppression in adults with cystic fibrosis. J Cyst Fibros. 2013;12(4):399-402.
72. Kasayama S, Otsuki M, Tanemura M, Fujita K, Miyatake A. Association of subclinical hypothalamic-pituitary-adrenal axis suppression with bone loss in patients with asthma taking inhaled corticosteroids. Ann Allergy Asthma Immunol. 2013;111(3):229-231.
73. Sacre K, Dehoux M, Chauveheid MP, et al. Pituitary-adrenal function after prolonged glucocorticoid therapy for systemic inflammatory disorders: an observational study. J Clin Endocrinol Metab. 2013;98(8):3199-3205.
74. Carruthers JA, August PJ, Staughton RC. Observations on the systemic effect of topical clobetasol propionate (Dermovate). Br Med J. 1975;4(5990):203-204.
75. Smith MJ, Hodson ME. Effects of long term inhaled high dose beclomethasone dipropionate on adrenal function. Thorax. 1983;38(9):676-681.
76. Ruiz Munoz LM, Amado J, Martin de Francisco AL, et al. Adrenocortical function and steroid doses in renal transplant patients. Dial Transplant. 1988;17(4):184-189.
77. Brown PH, Blundell G, Greening AP, Crompton GK. Do large volume spacer devices reduce the systemic effects of high dose inhaled corticosteroids? Thorax. 1990;45(10):736-739.
78. Shapiro R, Carroll PB, Tzakis AG, Cemaj S, Lopatin WB, Nakazato P. Adrenal reserve in renal transplant recipients with cyclosporine, azathioprine, and prednisone immunosuppression. Transplantation. 1990;49(5):1011-1013.
79. Brown PH, Blundell G, Greening AP, Crompton GK. Hypothalamo-pituitary-adrenal axis suppression in asthmatics inhaling high dose corticosteroids. Respir Med. 1991;85(6):501-510.
80. Kane KF, Emery P, Sheppard MC, Stewart PM. Assessing the hypothalamo-pituitary-adrenal axis in patients on long-term glucocorticoid therapy: the short synacthen versus the insulin tolerance test. QJM. 1995;88(4):263-267.
81. Broide J, Soferman R, Kivity S, et al. Low-dose adrenocorticotropin test reveals impaired adrenal function in patients taking inhaled corticosteroids. J Clin Endocrinol Metab. 1995;80(4):1243-1246.
82. Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S. Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J Allergy Clin Immunol. 1995; 96:571-579.
83. Kos-Kudla B. Iatrogenic adrenal cortex failure in patients with steroid dependent asthma in relation to different methods of glucocorticoid treatment. Endocr Regul. 1998;32(2):99-106.
84. Patel RS, Wallace AM, Hinnie J, McGarry GW. Preliminary results of a pilot study investigating the potential of salivary cortisol measurements to detect occult adrenal suppression secondary to steroid nose drops. Clin Otolaryngol Allied Sci. 2001;26(3):231-234.
85. Bonfils P, Halimi P, Malinvaud D. Adrenal suppression and osteoporosis after treatment of nasal polyposis. Acta Otolaryngol. 2006;126(11):1195-1200.
86. Holme J, Tomlinson JW, Stockley RA, Stewart PM, Barlow N, Sullivan AL. Adrenal suppression in bronchiectasis and the impact of inhaled corticosteroids. Eur Respir J. 2008;32(4):1047-1052.
87. Wilson KS, Gray CE, Cameron EH, Seth J, Parker AC. Hypothalamic/pituitary/adrenal function in patients treated with intermittent high-dose prednisolone and cytotoxic chemotherapy. Lancet. 1976;1(7960):610-612.
88. Masoli M, Weatherall M, Holt S, Shirtcliffe P, Beasley R. Inhaled fluticasone propionate and adrenal effects in adult asthma: systematic review and meta-analysis. Eur Respir J. 2006;28(5):960-967.
89. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med. 1999;159(9):941-955.
90. Habib GS. Systemic effects of intra-articular corticosteroids. Clin Rheumatol. 2009;28(7):749-756.
91. Seth J, Brown LM. A simple radioimmunoassay for plasma cortisol. Clin Chim Acta. 1978;86(1):109-120.
92. Carr PJ, Millar RP, Crowley H. A simple radioimmunoassay for plasma cortisol: comparison with the fluorimetric method of determination. Ann Clin Biochem. 1977;14(4):207-211.
93. Kohen F, Pazzagli M, Kim JB, Lindner HR. An immunoassay for plasma cortisol based on chemiluminescence. Steroids. 1980;36(4): 421-437.
94. Dufour-Rainfray D, Moal V, Cloix L, et al. Mass spectrometry for steroid assays [in French]. Ann Biol Clin (Paris). 2015;73(1):70-78.
95. Dinsen S, Baslund B, Klose M, et al. Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself. Eur J Intern Med. 2013;24(8):714-720.